

Product Name	: Lersivirine(UK 453061)
Synonyms	: Lersivirine UK-453061
Cat No.	: M21188
CAS Number	: 473921-12-9
Molecular Formula	: C17H18N4O2
Formula Weight	: 310.35
Chemical Name	: 5-((35-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl)oxy)isophthalonitrile
Description	Lersivirine(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy. (In Vitro):Lersivirine demonstrates excellent activity against large panels of wild type and drug-resistant HIV consistent with the encouraging profile demonstrated against the isolated RT enzymes.(In Vivo):Lersivirine (oral gavage; 0, 150, 350, and 500 mg/kg; once daily; gestation days 6 to 17, followed by cesarean section on gestation day 18.) allows induction of hepatic metabolizing enzymes at the first 2 days at 250 mg/kg, after which the dose is increased to 500 mg/kg/day in Mated Cr:CD1(ICR) mice. Lersivirine leads to skeletal variations which related to delayed development and decreased fetal ossifications.
Pathway	: Microbiology/Virology
Target	: HIV
Receptor	: HIV
Solubility	: DMSO:50 mg/mL (161.11 mM; Need ultrasonic)
SMILES	: <chem>CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1 .Davis J et al. The effect of lersivirine a next-generation NNRTI on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. Eur J Clin Pharmacol. 2012 Nov;68(11):1567-72.